Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...

In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share ...

GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

However, initial public offerings (IPOs) showed promise, with three companies pricing and closing the month at least at their offering price or higher. Notably, Metsera (MTSR, NC), an emerging ...

However, initial public offerings (IPOs) showed promise, with three companies pricing and closing the month at least at their offering price or higher. Notably, Metsera (MTSR, NC), an emerging player ...

In 2025, the global financial markets witnessed a resurgence in initial public offerings (IPOs), with several high-profile ... efficiency and expanding its packaged-food segment. Metsera Inc., a ...